Bausch + Lomb (BLCO)
Makes contact lenses, eye-care products, ophthalmic medicines, and surgical tools.
Something off on this page? Send us feedback.
Sells contact lenses, lens-care and over-the-counter eye-care products, ophthalmic medicines, and surgical equipment. The portfolio is organized around eye health, operates internationally, and remains a majority-controlled subsidiary of Bausch Health.
Products span contact lenses, lens care, and over-the-counter eye-care products, alongside ophthalmic medicines and surgical devices and instruments. The integrated portfolio serves vision care, pharmaceutical, and surgical uses across international markets. Its offerings are intended to address eye-health needs across different stages of life.
Founded in 1853, the business grew from optical goods into eye health through soft contact lenses, lens-care brands, ophthalmic pharmaceuticals, and surgical capabilities. It operates through a broad product portfolio rather than a single-category franchise.
Bausch Health retains controlling ownership, so the company remains a subsidiary despite its NYSE listing.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | Leerink Partners | Target | Target: — | Target: $24 |
| Aug 3, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $20 | Target: $21 |
| Jul 30, 2026 | UBS | Reiterate | Rating: —Target: $21 | Target: $23 |
| Jul 28, 2026 | UBS | Initiate | Rating: —Target: — | Target: $21 |
| Jul 6, 2026 | Evercore ISI | Target | Target: $18 | Target: $17 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $367.0M · Total debt $5.12B · Total assets $13.86B · Shareholders' equity $6.38B
- Revenue
- $1.39B
- Operating income
- $83.0M
- Net income
- −$14.0M
No dividends on record.
| Institutions | 10.69% | 38.18M shares | |
|---|---|---|---|
| 102 holders · as of Jun 30, 2026 | |||
| Insiders | 0.89% | 3.16M shares | |
| 22 holders · as of Aug 14, 2026 | |||
| Strategic holders | 86.92% | 310.45M shares | |
| 1 holder · as of Feb 14, 2023 | |||
| Other | 1.50% | 5.37M shares | |
| remainder | |||
357.17M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Bausch Health Companies Inc.Strategicdirector | 86.92% | 310.45M | filed Feb 14, 2023 |
Icahn Carl CInstitution | 0.98% | 3.50M | as of Jun 30, 2026 |
Oaktree Capital Management LPInstitution | 0.96% | 3.44M | as of Jun 30, 2026 |
Deutsche Bank AG\Institution | 0.96% | 3.42M | as of Jun 30, 2026 |
D. E. Shaw & Co., Inc.Institution | 0.93% | 3.32M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 10, 2026 | Frederick Munsch | officer: SVP, Controller and CAO | −52,900 | $16.78 |
| Aug 7, 2026 | Andrew C. von Eschenbach | director | −6,059 | $16.58 |
| Aug 6, 2026 | Andrew C. von Eschenbach | director | −12,500 | $16.50 |
| Mar 6, 2026 | Brent L. Saunders | director, officer: CEO and Chairman of the Board | +14,700 | $17.14 |
| Mar 6, 2026 | Sam Eldessouky | officer: EVP and CFO | +4,000 | $17.13 |
- Alcon
Broad eye-care peer in contact lenses, ocular health, and surgery
- Johnson & Johnson
ACUVUE lenses and Vision surgery overlap in two core eye-care markets
- CooperCompanies
Specialist soft-contact-lens rival across daily, toric, and multifocal wear
- Glaukos
Glaucoma, corneal, and retinal therapy peer spanning devices and drugs
- AbbVie
Eye-care drug and ocular-surface peer in prescription and consumer treatment
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Bausch + Lomb | $17.23 | −0.52% | $6.19B | — | 17.3 | 1.2 | +9.1% |
| Alcon | $65.42 | −0.26% | $31.99B | 50.5 | 17.2 | 3.0 | +7.5% |
| Johnson & Johnson | $270.95 | +0.65% | $648.72B | 31.2 | 22.8 | 6.6 | +6.6% |
| CooperCompanies | $55.11 | −0.32% | $10.78B | 18.9 | 12.0 | 2.5 | +0.6% |
| Glaukos | $159.61 | −0.16% | $9.43B | — | 1,248.3 | 15.4 | +49.5% |
| AbbVie | $267.13 | +0.72% | $468.77B | 74.8 | 17.6 | 7.3 | +10.2% |
| Median | 40.8 | 17.6 | 6.6 | +7.5% |